Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

The study’s patient demographics were consistent with prior studies of other agents in hypertrophic cardiomyopathy (HCM) and with real-world clinical practice. Mean baseline KCCQ-CSS was 59, indicating considerable symptom burden at study entry; no treatment outcomes or comparative efficacy data are provided in the excerpt.